Whereas some miRNAs can be used as a marker of urological [78] or prostate [79] cancer diagnosis, plasmatic miRNA-210 negatively correlates with the EPO resistance index and is considered to be a prognostic marker of EPO responsiveness and an index for anemia management in hemodialyzed end-stage renal disease patients [80]. This evidence concerns the gene EPO and chronic kidney disease.